Last reviewed · How we verify
D. Midazolam
GABA_A receptor agonist
GABA_A receptor agonist Used for Anesthesia, Sedation.
At a glance
| Generic name | D. Midazolam |
|---|---|
| Also known as | CAS No. 59467-96-8 |
| Sponsor | Paion UK Ltd. |
| Drug class | Benzodiazepine |
| Target | GABA_A receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Midazolam acts as a potent agonist at the GABA_A receptor, enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) and leading to sedative, hypnotic, and anxiolytic effects.
Approved indications
- Anesthesia
- Sedation
Common side effects
- Respiratory depression
- Confusion
- Dizziness
Key clinical trials
- Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery (PHASE1)
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (PHASE1)
- Ketamine, SGB and Combination Treatment for TBI (PHASE2)
- Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (PHASE3)
- Comparison of Effect of Dexmedetomidine and Midazolam on Emergence Agitation (NA)
- Comparison of Oral Dexmedetomidine, Ketamine Versus Midazolam for Premedication in Children Undergoing Injuinal Surgeries (NA)
- Melatonin vs Midazolam in Children Undergoing Tonsillectomy (PHASE3)
- Intravenous Dexmedetomidine Versus Midazolam in Preventing Shivering in Trauma Patients Undergoing Lower Limb Orthopedic Surgery Under Spinal Anesthesia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D. Midazolam CI brief — competitive landscape report
- D. Midazolam updates RSS · CI watch RSS
- Paion UK Ltd. portfolio CI